What question did this study set out to answer?

June 7, 2026

1557-P: Diabetes Technology Use and the Acute Living Experience of Persons with Type 1 Diabetes

RCREBECCA BAQIYYAH CONWAYThe Medical Center of Aurora KVKELLY VALDEZThe Medical Center of Aurora PMPORTIA A. MENSAHThe Medical Center of Aurora

Key Points

This research assesses how the use of diabetes technology affects the acute living experience of persons with type 1 diabetes, particularly among different racial and ethnic groups.
Participants aged 14 to 40 (n=724) completed surveys on diabetes technology use, diabetic ketoacidosis, hypoglycemia, and related psychological measures.
Techuse was defined as using either continuous glucose monitors with continuous subcutaneous insulin infusion or automated insulin delivery systems.
Statistical analysis examined differences in glycemic control and acute diabetes-related events by race and technology use.
79% of Non-Hispanic White, 66% Non-Hispanic Black, and 67% Hispanic Americans reported techuse.
Techuse was associated with lower HbA1c (p=0.007) and decreased odds of DKA in Non-Hispanic White (OR=0.32), with variable effects for other groups.
Techuse linked to significantly lower odds of hypoglycemia (OR=0.44) and increased insulin treatment satisfaction (p<0.001).

Abstract

Introduction and Objective: Technologies such as continuous glucose monitors (CGM), continuous subcutaneous insulin infusion (CSII) and automated insulin delivery systems (AID) enhance diabetes management. While this may improve long-term survival, how this translates into the more acute experience of persons w/ diabetes (PwD) may be variable. We assessed how diabetes technology use is associated w/ the acute living experience of PwD and whether it differently affects certain groups defined by race/ethnicity. Methods: Participants aged 14 to 40 (n=724) were invited complete online surveys about diabetes technology use (techuse), life threatening diabetic ketoacidosis (DKA) and severe hypoglycemia in the past yr, and the following: T1D distress (T1DD), Diabetes Self Monitoring (DSM), Glucose Management Experience (GME), and Insulin Treatment Satisfaction (ITS) Questionnaires. Techuse was defined as the combined use of CGM + CSII, or AID. Results: Techuse was reported in 79% of Non-Hispanic White (NHW), 66% of Non-Hispanic Black (NHB), and 67% of Hispanic Americans. Most recent HbA1c was lower in techusers overall (p=0.007). The greatest differences were observed in NHB Americans (p-interaction=0.04). Mean HbA1c (%) by techuse was as follows: 6.9 vs 7.3 (p=0.007) for NHW; 7.8 vs 9.2 (p=0.07) for NHB; and 8.0 vs 8.5 (p=.23) for Hispanic participants. Techuse was associated w/ lower odds of DKA in NHW (OR=0.32, 0.15-0.71), a marginally higher odds in NHB (OR=1.95, 0.36-10.46) and no differences in Hispanic participants (OR=1.02, 0.31-3.39), (p-interaction=0.03). Techuse was linked to a significantly lower odds of hypoglycemia (OR=0.44, 0.21-0.92) overall w/ no variation by race. Techuse was not linked w/ T1DD, DSM score, or GME (all p-values0.05), but was associated w/ increased ITS (p0.001); these relationships did not vary by race. Conclusion: Diabetes technology use is linked to lower HbA1c, hypoglycemia and DKA, those this varies by race, w/ greater reductions in HbA1c in NHB and DKA in NHW Americans, and increased insulin treatment satisfaction in all races. Disclosure R. Conway: None. K. Valdez: None. P.A. Mensah: None. C. Chartier-Logan: None. J. Snell-Bergeon: None. Funding American Diabetes Association (11-22-ICTSHD-03)

AIに質問

Bookmark

View Full Paper